New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

This was followed by Merck & Co’s Keytruda (pembrolizumab) and a gang of rival PD-L/PD-L1 checkpoint inhibitors, which have set new standards in cancer care in many different forms of the disease.

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai. The ...

Three thousand six hundred seven patients were included. The median follow-up was 34 months. Pairwise disease comparison demonstrated no significant survival difference between N1a and N2a subgroups.

Over a short period in the late 1990s, three groups converged on the discovery of a neuropeptide system, centred in the dorsolateral hypothalamus, that regulates arousal states, influences feeding ...